Drugs / EYS606
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04207983 | Feb 2020 → Oct 2021 | uveitis | Eyevensys | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EYS606 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04207983 ↗ |
| Known as | pEYS606 | “Two administrations of EYS606 (135μg pEYS606/90 μL). The frequency between the two administrations will be determined by the DSMB upon completion of the Part I safety cohorts.” NCT04207983 ↗ |
| Modality | Other / unclassified | “EYS606 is a DNA plasmid solution administered by electrotransfection into the ciliary muscle” NCT04207983 ↗ |
| Route | Other | “administered by electrotransfection into the ciliary muscle” NCT04207983 ↗ |